Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Ethinylestradiol

Generic name
Ethinylestradiol
Brand name
ATC Code
G03CA01

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Constitutional tall height in girls
  • Oral
    • ≥ 9 years
      • Initial dose: Medicinal treatment is not preferred for this indication because of the long term side-effects on fertility. In individual cases it can be prescribed by a paediatric endocrinologist after careful consideration, after the parents have been informed.  50 microg./day in 1 dose For 1 week.
      • Maintenance dose: Build up after 1 week to 100 - 200 microg./day in 1 dose. Max: 200 microg./day.
      • Duration of treatment:

        Continue treatment until epiphyseal discs are completely closed.

      • The first 10-14 days of the month combined with medroxyprogesterone, 10 mg/day in a single dose.
Puberty induction in girls with Turner’s syndrome
  • Oral
    • From bone ages of ≥ 12 years
      • Initial dose: 0.05 microg./kg/day in 1 dose
      • Maintenance dose: Slow increase PER YEAR by 0.05 microg./kg/day in 1 dose
Puberty induction in pubertas tarda: hypogonadism
  • Oral
    • ≥ 11 years
      • 0.05 microg./kg/day in 1 dose
        • Increase every 6-9 months until breakthrough bleeding occurs.
        • Build-up regimen: 2 mcg, 5 mcg, 10 mcg, 15 mcg, 20 mcg
        • Add medroxyprogesterone in breakthrough bleeding or after 1-2 years. When the adult dosage of 20 mcg ethinylestradiol is reached, switch to a combination pill or a contraceptive pill.
Priming before a growth hormone test
  • Oral
    • ≥ 8 years
      • 50 microg./day in 2 doses.
      • Duration of treatment:

        3-5 days

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The treatment for constitutionally tall women gives an increased risk of fertility disorders and unwanted childlessness. Only to be prescribed in individual cases by a paediatric or other endocrinologist, after careful consideration of the risks and after consultation with parents about the risks.

Prior to treatment, the skeletal age should be determined and an accurate adult final height prognosis should be calculated. Periodic checks (e.g. twice a year) of the epiphyseal discs by X-rays of the non-dominant hand and wrist are recommended during treatment. 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Natural and semisynthetic estrogens, plain
G03CA03
G03CA04
G03CA57
NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN
G03CA03
G03CA04
G03CA57

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. NV Organon, SPC Lynoral (RVG 00022), www.cbg-meb.nl, Geraadpleegd 14 juli 2010, http://db.cbg-meb.nl/IB-teksten/h00022.pdf
  2. Nederlandse Groeistichting en de Adviesgroep Groeihormoon van de Nederlandse Vereniging Kindergeneeskunde, Behandeling van kleine lengte bij meisjes met Turner syndroom, www.nvk.nl, mei 2005, http://www.nvk.nl/Kwaliteit/Richtlijnenenindicatoren/Richtlijnen/Turnersyndroomvan/tabid/370/language/nl-NL/Default.aspx
  3. Noordam C et al, Werkboek Kinderendocrinologie, digitale publicatie op www,nvk.nl (alleen leden), 2010
  4. Hendriks AEJ, et al, Fertility and Ovarian Function in High-Dose Estrogen- Treated Tall Women, J Clin Endocrinol Metab, 2011, Apr 96 (4), 1098-105

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes